Literature DB >> 2354592

Pharmacokinetics of fluconazole in patients undergoing continuous ambulatory peritoneal dialysis.

D Debruyne1, J P Ryckelynck, M Moulin, B Hurault de Ligny, B Levaltier, M C Bigot.   

Abstract

The pharmacokinetics of fluconazole given orally (100 mg) or intraperitoneally (50 and 150 mg) were determined in 15 patients with chronic renal failure who were undergoing continuous ambulatory peritoneal dialysis. The half-life (72 to 85 hours) was intermediate between values obtained in healthy volunteers and in patients with renal insufficiency studied during an interhaemodialysis period. The peritoneal clearance, 0.26 to 0.33 L/h, led to an 18% recovery of administered drug in the dialysates after 48 hours. The peritoneal absorption was slow (time to peak plasma concentration 7 hours) but the peritoneal bioavailability was excellent at 87 +/- 5%. The mean concentrations of fluconazole up to 24 hours were 770 and 1900 micrograms/L after single intraperitoneal doses of 50 and 150 mg, respectively. The volume of distribution (40 to 60 L) did not differ from that determined in patients with normal renal function. In the case of fungal peritonitis essentially attributed to Candida spp., a 6-hour intraperitoneal infusion of fluconazole 150 mg every 2 days appears to be a good regimen to rapidly exceed minimum inhibitory concentrations and treat infection without risk of systemic dissemination of fungi or toxicity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2354592     DOI: 10.2165/00003088-199018060-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  13 in total

1.  Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits.

Authors:  J R Perfect; D T Durack
Journal:  J Antimicrob Chemother       Date:  1985-07       Impact factor: 5.790

2.  Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans.

Authors:  M J Humphrey; S Jevons; M H Tarbit
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

3.  Pharmacokinetics of piperacillin in patients on peritoneal dialysis with and without peritonitis.

Authors:  D Debruyne; J P Ryckelynck; B Hurault De Ligny; M Moulin
Journal:  J Pharm Sci       Date:  1990-02       Impact factor: 3.534

Review 4.  Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  T W Paton; W R Cornish; M A Manuel; B G Hardy
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

5.  Antifungal effects of fluconazole (UK 49858), a new triazole antifungal, in vitro.

Authors:  F C Odds; S L Cheesman; A B Abbott
Journal:  J Antimicrob Chemother       Date:  1986-10       Impact factor: 5.790

6.  Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome.

Authors:  A M Sugar; C Saunders
Journal:  Am J Med       Date:  1988-10       Impact factor: 4.965

7.  Determination of fluconazole in biological fluids by capillary column gas chromatography with a nitrogen detector.

Authors:  D Debruyne; J P Ryckelynck; M C Bigot; M Moulin
Journal:  J Pharm Sci       Date:  1988-06       Impact factor: 3.534

Review 8.  Fungal peritonitis in patients receiving peritoneal dialysis: experience with 11 patients and review of the literature.

Authors:  E S Eisenberg; I Leviton; R Soeiro
Journal:  Rev Infect Dis       Date:  1986 May-Jun

Review 9.  Azole antifungal agents: emphasis on new triazoles.

Authors:  M S Saag; W E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

10.  A prospective study of the efficacy of fluconazole (UK-49,858) against deep-seated fungal infections.

Authors:  J W Van't Wout; H Mattie; R van Furth
Journal:  J Antimicrob Chemother       Date:  1988-05       Impact factor: 5.790

View more
  8 in total

1.  Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.

Authors:  D Debruyne
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

Review 2.  Fungal peritonitis in children on peritoneal dialysis.

Authors:  Renske Raaijmakers; Cornelis Schröder; Leo Monnens; Elisabeth Cornelissen; Adilla Warris
Journal:  Pediatr Nephrol       Date:  2006-11-17       Impact factor: 3.714

Review 3.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

4.  Elimination of fluconazole during continuous veno-venous haemodialysis (CVVHD) in a single patient.

Authors:  K Wolter; G Marggraf; H Dermoumi; E Fritschka
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics of fluconazole.

Authors:  D Debruyne; J P Ryckelynck
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

6.  Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration.

Authors:  Kazuaki Yagasaki; Satoshi Gando; Naoyuki Matsuda; Takashi Kameue; Toshiteru Ishitani; Takeshi Hirano; Ken Iseki
Journal:  Intensive Care Med       Date:  2003-09-13       Impact factor: 17.440

Review 7.  Pharmacokinetic optimisation of oral antifungal therapy.

Authors:  M Schäfer-Korting
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

8.  Fluconazole is removed by continuous venovenous hemofiltration in a liver transplant patient.

Authors:  J Scholz; M Schulz; M Steinfath; S Höver; H Bause
Journal:  J Mol Med (Berl)       Date:  1995-03       Impact factor: 4.599

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.